Smarter Cancer Care
In collaboration with thousands of physicians around the world, over one million patients improved their outcomes with the Oncotype IQ portfolio of genomic tests.
Learn More

Post-SABCS Webinar

Jan. 14, 2021, 7-8pm ET / 4-5pm PT

Join Dr. Christy Russell for a webinar reviewing data presented at SABCS 2020: "Enhancing the Utility of the Oncotype DX Breast Recurrence Score Test."

Shaping Clinical Practice: ADAPT and RSClin

Presented at SABCS 2020

  • Five-year outcomes from ADAPT study show that not all clinically high-risk patients with node-negative or node-positive disease need chemotherapy
  • New patient-specific meta-analysis provides individualized estimates for both prognosis and absolute chemotherapy benefit in node-negative breast cancer
    •

    Landmark RxPONDER Trial Results

    Presented at the 2020 SABCS

    Learn more about the data from the RxPONDER trial and how it successfully defines the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score results of 0 to 25.

    SABCS 2020 Virtual Symposium

    Exact Sciences Showcases Continued Progress in Cancer Diagnostics

    See new data for the Oncotype DX Breast Recurrence Score test and how it changes treatment decisions for patients with early-stage breast cancer.
    Real People.
    Real Results.
    When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
    Learn More
    New Pan-Cancer Tissue Test
    The Oncotype MAP Pan-Cancer Tissue Test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer.
    LEARN MORE
    Our Response to COVID-19
    Oncotype DX tests remain readily available and that our laboratory continues to operate. Our patient-critical work teams continue to operate, following all safety procedures and practices.
    LEARN MORE
    Healthcare Savings
    Ineffective cancer treatments exact human as well financial costs. Oncotype IQ tests have saved more than $3.5 billion in the US.
    Learn More

    Stay in Touch

    Have questions? We're here to help.

     Contact Us
    Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
    In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
    Making cancer care smarter.™
    X

    We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.